← Back to headlines

Merck's New Cancer Drug Shows Strong Results in Phase 3 Trials
Merck announced that its new cancer drug, sac-TMT, has demonstrated strong results in phase 3 trials. The drug offers new hope for patients battling advanced or recurrent aggressive endometrial cancers.
20 May, 11:00 — 20 May, 11:00



